A.P. Pharma, Inc. (NASDAQ: APPA) 52.2% LOWER; today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting. APF530 is a long-acting formulation of granisetron utilizing the Company’s proprietary Biochronomer™ drug delivery system. A conference call has been scheduled for Friday, March 19, 2010 at 9:00 a.m. Eastern Time.

Gentium S.p.A (Nasdaq: GENT) 37.4% HIGHER; shares are surging higher this morning on no news. Volume is already more than 15x normal. Notably, shares have